Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks presented new Phase 1 data for its FRα-targeting ADC ZW191 at ESMO 2026, showing a confirmed objective response rate of 64.5% at the 6.4 mg/kg dose in heavily pretreated patients with high-grade serous platinum-resistant ovarian cancer. Responses were durable, with median duration of response not yet reached and six-month progression-free survival of 61% in both dose groups, and activity was seen across high, intermediate, and low/negative FRα expression levels. Tolerability favored the 6.4 mg/kg dose (22% vs 44% Grade 3+ treatment-related adverse events), informing dose selection for further development.
Key figures
- Drug Name
- ZW191
- Phase Of Trial
- Phase 1
- Corr 6.4mg kg
- 64.5%
- Corr 9.6mg kg
- 55.3%
- Six month pfs
- 61%
- Median followup
- 7 months
- Median pfs 6.4mg
- 7.9 months
- Median pfs 9.6mg
- 9.8 months
- Patients analyzed
- 80
- Grade3plus trae 6.4mg
- 22%
- Grade3plus trae 9.6mg
- 44%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.